Avid Bioservices Inc (CDMO)

[keep_trying]

Jessme, the content of the Duke study report is something that we can only speculate about using bits of information that were shared by PPHM in investor conference calls and things being reported at conferences and such.

My speculation about the Duke paper content was highlighted in some email exchanges I did last week with Realist1.

Duke was suggested to be doing monkey studies with PPHM supplied MABS that included Bavi and , we presume, other PPHM products in the Bavi family. The recent articles being posted that emphasize the role of an amino acid (PS) in enabling viruses to evade the immune system are a lead in to what the Duke paper might address. We know from Dr. Thorpe's published work that Bavi seeks out and preferentially attaches itself to exposed PS. PPHM sponsored studies have already indicated that, once Bavi is attached to the PS, the bodies immune system can recognize the "invader" that was masking itself with the body's own "waste" PS. I am speculating that the Duke paper will tie everything together (PS, Bavi and immune response). If done in a manner that addresses the expected concerns and reservations of the scientific community, the Duke paper can celiver an important proof of concept plus a path to further funding and trial developments. PPHM's Phase 2 trial results, if successful, should take on greater meaning and acceptance as a result, increasing the prospects that Pharma competition for PPHM products will develop.

I hope the Duke paper is delivered in a manner that is timely and reinforcing to the pending results of the PPHM Phase 2 trials. Jazz has posted some better characterizations than what I just wrote, if this doesn't answer your question.

Best wishes and IMO.

KT